Intuitive Surgical stock (US4612021034): earnings and procedure growth keep da Vinci story in focus

Intuitive Surgical reported continued growth in procedures performed with its da Vinci robotic systems in its recent quarterly updates, alongside higher revenue and an expanding installed base of systems, according to company filings and earnings materials published in 2025 on its investor relations site and coverage by major financial media as of 04/18/2025Intuitive investor materials as of 04/18/2025Reuters as of 04/18/2025.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

Intuitive Surgical: core business model

Intuitive Surgical focuses on robotic-assisted minimally invasive surgery, with its da Vinci platform used across multiple procedures such as urology, general surgery and gynecology. The company designs, manufactures and services robotic systems and offers training and support for surgeons, nurses and hospital staffCompany website as of 03/15/2025.

The core of the business model revolves around a razor-and-blade structure: hospitals purchase or lease da Vinci systems, while recurring revenue comes from instruments, accessories and services required on a per-procedure basis. This mix has historically produced a growing share of recurring revenue as the installed base expands and utilization rises, according to company presentations published in 2024 and 2025Intuitive earnings presentation as of 10/19/2024.

In addition to da Vinci, Intuitive offers Ion, a platform for minimally invasive lung biopsies that targets the diagnosis of lung lesions. This platform expands the company’s reach into pulmonology and diagnostic workflows, complementing its core surgical offering, according to product information updated in 2024Ion product information as of 11/12/2024.

Main revenue and product drivers for Intuitive Surgical

Revenue at Intuitive is divided into three main buckets: system sales, instruments and accessories, and services. Instruments and accessories are tied to each procedure, and services cover maintenance and support contracts for installed systems. In recent reporting periods, the company has indicated that instruments, accessories and services account for a majority of total revenue, reflecting the ongoing utilization of its installed baseQuarterly results as of 01/25/2025.

System placements remain a key growth driver because they expand the installed base and future demand for instruments and services. Intuitive has reported rising placements of da Vinci systems in the US and internationally, with particular emphasis on adoption in general surgery and bariatric procedures during 2024 and early 2025. Higher procedure volumes per system add operating leverage as hospitals spread fixed costs over more cases, according to management commentary in earnings calls published in 2024Intuitive presentations as of 10/19/2024.

Procedure growth is a closely tracked metric. Intuitive has disclosed double-digit growth in da Vinci procedures in recent years, driven by higher utilization in the United States and increased adoption in markets such as Japan and Europe. In its 2024 and early 2025 updates, the company highlighted particular strength in hernia repair and colorectal procedures, while still seeing a meaningful contribution from urology, according to filings and presentation slides released alongside its resultsProcedures update as of 01/25/2025.

Conclusion

Intuitive Surgical has built a leading position in robotic-assisted surgery, with earnings and procedure updates from 2024 and 2025 underlining the importance of recurring revenue from instruments, accessories and services. For US investors, the stock offers exposure to hospital capital spending, medical technology innovation and the broader trend toward minimally invasive care, but it also depends on continued procedure growth, reimbursement stability and competitive dynamics in surgical robotics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.